Study reveals tricky platelet swings in blood disorder drug response
NCT ID NCT05876221
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked back at 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab (Cablivi). The drug quickly normalizes platelet counts, but some patients experience a sharp rise then a dip, which might mislead doctors into giving unnecessary extra treatment. The goal was to identify these patterns and help guide safer, more accurate care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Caplacizumab (Cablivi)
What this could lead to
If successful, this could help doctors better interpret platelet counts during caplacizumab treatment, reducing unnecessary therapy adjustments and side effects.
What could go wrong
This is a retrospective analysis, not a controlled trial, so it cannot prove cause and effect. The findings may not apply to all patients or change current practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Cologne
Cologne, Germany